Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 20Lymphoid 4Gastrointestinal 4Thoracic 2Plasma cell 2Other hematologic neoplasm 2Myeloid 2Head & Neck 2Gynecologic 2Genitourinary 2Dermatologic 2Sarcoma 1Classical hematology 1CNS 1

Conditions

Melanoma 250Uveal Melanoma 29Neoplasm Metastasis 22Skin Neoplasms 17Brain Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Carcinoma, Merkel Cell 10Neoplasms 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Triple Negative Breast Neoplasms 7Carcinoma, Hepatocellular 7Uterine Cervical Neoplasms 6Colorectal Neoplasms 6Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 5Stomach Neoplasms 5Lung Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Kidney Neoplasms 4Carcinoma, Basal Cell 4Sarcoma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Liver Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Vulvar Neoplasms 2

Interventions

pembrolizumab 21Cyclophosphamide 18fludarabine 8Radiotherapy 8Radiosurgery 7Nivolumab 7poly ICLC 6fludarabine phosphate 6aldesleukin 6Therapeutics 6Paclitaxel 6Magnetic Resonance Spectroscopy 6durvalumab 5Psychiatric Rehabilitation 5Interleukin-2 5Drug Therapy 5Docetaxel 5Cisplatin 5temsirolimus 4cemiplimab 4Trastuzumab 4Temozolomide 4Sirolimus 4Gemcitabine 4Flow Cytometry 4Filgrastim 4Carboplatin 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Ipilimumab × Dermatologic × Clear all
NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Lytix Biopharma AS

Phase 1 Completed
80 enrolled
BreastDermatologicHead & NeckLymphoid

Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡